Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLY-200 in Type 2 Diabetic Patients
NCT05478525Phase 2Completed
- Sponsor
- Glyscend Therapeutics
- Start
- Aug 2022
- Primary completion
- Mar 2023
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GLY-200 in type 2 diabetes mellitus (T2DM), sponsored by Glyscend Therapeutics. Started Aug 2022; status: completed.
02
Drugs
GLY-200
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05478525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05478525.